Prometheus Biosciences has developed anti-CD30L antibodies for treating autoimmune diseases like inflammatory bowel disease. The patent includes specific amino acid sequences for the antibody’s variable regions. GlobalData’s report on Prometheus Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Prometheus Biosciences, Molecular diagnosis biomarkers was a key innovation area identified from patents. Prometheus Biosciences's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-cd30l antibodies for autoimmune disease treatment
A recently granted patent (Publication Number: US11866505B2) discloses an antibody or antigen binding fragment that binds CD30L. The antibody comprises specific amino acid sequences for heavy chain variable region complementarity determining regions (CDR-H1, CDR-H2, CDR-H3) and light chain variable region complementarity determining regions (CDR-L1, CDR-L2, CDR-L3). The patent further details variations of the antibody with different amino acid sequences for the CDR regions, providing a comprehensive framework for the development of antibodies targeting CD30L.
Additionally, the patent outlines the composition of the antibody, including the VH and VL regions with specific amino acid sequences. It also describes the presence of an IgG constant region in the antibody, with variations that affect antibody-dependent cell-mediated cytotoxicity (ADCC) function and complement-dependent cytotoxicity (CDC) compared to human IgG1. The patent covers different types of IgG antibodies, such as IgG1, IgG2, IgG3, or IgG4, and specifies that the antibody can be human, chimeric, or humanized, broadening the scope of potential applications for this novel antibody targeting CD30L.
To know more about GlobalData’s detailed insights on Prometheus Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
